Pharmacologic class (EPC) · 2 drug pages

Noncompetitive AMPA glutamate receptor antagonist: adverse event reports filed with FDA

4,967 reports list a drug in this class as a suspect or interacting product, 2012–2026.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

4,967
reports across the class: 0% of all reports; 478
reports, 12 months to June 2026: 499 in the 12 months before; 84.5%
marked serious by the reporter: 57.4% across all reports; 2
drugs with a page: brand and generic names counted separately

Noncompetitive AMPA glutamate receptor antagonist is a pharmacologic class (an FDA Established Pharmacologic Class) with 2 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 4,967 adverse event reports received by FDA, 0% of the database, from December 2012 to June 2026.

478 reports arrived in the 12 months to June 2026, close to the 499 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 84.5% of the class's reports are marked serious, 5.4% record death among the outcomes and 39.6% record hospitalisation, as reported.

Across the class the reactions recorded most often are drug ineffective (16.1%), seizure (10.8%) and off label use (8.9%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.

The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Drugs in the class

Drug	Name type	Reports	Latest 12 months	Marked serious	Top term recorded
FycompaPerampanel	brand	3,059	225	79.1%	Aggression
Perampanel	generic	1,908	253	93.1%	Drug ineffective

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Reactions recorded across the class

share of class reports recording the termmedian drug in the class

Drug ineffectivethe medicine did not work as expected16.1%798
Seizurea fit or convulsion10.8%536
Off label useused for a purpose or in a way not on the label8.9%444
Aggressionaggressive behaviour8.9%443
Somnolencedrowsiness6.2%307
Multiple-drug resistance5.8%287
Dizzinesslight-headedness or unsteadiness5.5%274
Drug interactionan interaction between medicines5.2%259
Status epilepticus4.9%242
Irritabilityirritability4%200
Suicide attempta suicide attempt4%199
Suicidal ideationthoughts of suicide3.9%195
Fatiguetiredness3.9%194
Epilepsy3.5%172
Condition aggravatedthe condition being treated got worse3.3%163
Intentional overdosea deliberate overdose3.1%154
Gait disturbancedifficulty walking2.8%140
Psychotic disordera loss of contact with reality2.6%130
Product use in unapproved indicationused for a purpose not on the label2.4%121
Agitationrestlessness2.4%120
Anger2.4%119
Falla fall2.3%116
Drug resistance2.3%115
Toxicity to various agentspoisoning or toxic effect of one or more substances2%98
Cognitive disorderproblems with thinking or memory1.9%95

Solid bar: share of all class reports. Hollow bar: the median share across the 2 member drugs, the reference used on each member's page. One report can record several terms.

Outcomes, patients and reporters

Outcomes recorded

Death5.4%269

Life-threatening7.5%372

Hospitalisation (initial or prolonged)39.6%1,967

Disability2%101

Congenital anomaly0.9%47

Other serious51.3%2,548

Not serious15.5%770

Patient age

Under 22.5%124

2 to 117.5%373

12 to 177.9%390

18 to 4431.8%1,579

45 to 6413.5%671

65 to 744.6%230

75 and over2.9%144

Age not given29.3%1,456

Who reported

Physician50%2,485

Pharmacist4.4%219

Other health professional31.7%1,577

Lawyer0%1

Consumer or non-health professional13.1%652

Not given0.7%33

Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.

Questions about Noncompetitive AMPA glutamate receptor antagonist reports

Which drugs are in the Noncompetitive AMPA glutamate receptor antagonist class on this site?

Fycompa and Perampanel. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.

How many reports does the class have?

4,967 reports through June 2026, 478 of them in the latest 12 months. A report listing two drugs of the class counts once for each.

What reactions are recorded most often?

drug ineffective (16.1%), seizure (10.8%), off label use (8.9%), aggression (8.9%) and somnolence (6.2%).

Can the members table be used to rank the drugs?

No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.

How do I report an adverse event?

Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.